---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-23-022345"
form_type: "8-K"
ticker: "ZVRA"
cik: "0001434647"
company_name: "ZEVRA THERAPEUTICS, INC."
filed_at: "2023-08-07T23:59:59+00:00"
generated_at: "2026-06-12T04:02:49.437621+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Zevra Therapeutics appoints Thomas Anderson to board; Matthew Plooster resigns

## Summary
- Thomas Anderson appointed Class III director effective August 7, 2023; term expires at 2024 annual meeting.
- Anderson is CEO of SwanBio Therapeutics and former chief commercial strategy officer at Sage Therapeutics.
- Anderson receives initial option for 58,800 shares vesting over 3 years and $40,000 annual retainer.
- Matthew R. Plooster resigned from the board effective immediately upon Anderson's appointment.

## SEC filing metadata
- accession: 0001437749-23-022345
- form_type: 8-K
- ticker: ZVRA
- cik: 0001434647
- company_name: ZEVRA THERAPEUTICS, INC.
- filed_at: 2023-08-07T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1434647/000143774923022345/0001437749-23-022345-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1434647/000143774923022345/zvra20230807c_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-23-022345
- JSON: https://secwatch.observer/filing/0001437749-23-022345.json
- Plain text: https://secwatch.observer/filing/0001437749-23-022345.txt

## Key facts
- Executive change
  Matthew R. Plooster resigned as member of the Board at ZEVRA THERAPEUTICS, INC..
  - Action: resigned
  - Role: member of the Board
  source text: On August 7, 2023, Matthew R. Plooster, a member of the Board of the Company, resigned from such position, effectively immediately after the appointment of Mr. Anderson.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1434647/000143774923022345/0001437749-23-022345-index.htm
- Executive change
  Thomas Anderson was appointed as Class III director at ZEVRA THERAPEUTICS, INC..
  - Action: appointed
  - Role: Class III director
  source text: On August 7, 2023, the board of directors (the “Board”) of Zevra Therapeutics, Inc. (the “Company”) appointed Thomas Anderson to serve as a director of the Company, effective immediately.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1434647/000143774923022345/0001437749-23-022345-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.